-0.40 (-1.40%)

POWR Rating

Component Grades













Filter CSTL News Items

CSTL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CSTL News Highlights

  • CSTL's 30 day story count now stands at 3.
  • Over the past 14 days, the trend for CSTL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CSTL are SKIN.

Latest CSTL News From Around the Web

Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023

FRIENDSWOOD, Texas, January 23, 2023--Castle's medical director, Matthew Goldberg, M.D., F.A.A.D., will present at the Precision Medicine World Conference (PMWC®) 2023 on Jan. 25.

Yahoo | January 23, 2023

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

FRIENDSWOOD, Texas, January 17, 2023--Castle is sharing new data supporting the clinical value of their skin cancer tests at the 2023 Winter Clinical Dermatology Conference - Hawaii®.

Yahoo | January 17, 2023

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

FRIENDSWOOD, Texas, January 09, 2023--Castle Biosciences today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022.

Yahoo | January 9, 2023

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

FRIENDSWOOD, Texas, November 21, 2022--Castle announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory in Pittsburgh.

Yahoo | November 21, 2022

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

FRIENDSWOOD, Texas, November 17, 2022--Castle announced the publication of a study in collaboration with the MRF to assess patient experiences with prognostic testing in uveal melanoma.

Yahoo | November 17, 2022

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

FRIENDSWOOD, Texas, November 15, 2022--Castle announced new data showing the independent and significant risk-stratification of DecisionDx-SCC in cSCC tumors with ambiguous histology.

Yahoo | November 15, 2022

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

FRIENDSWOOD, Texas, November 14, 2022--Castle Biosciences has been named a Houston Chronicle Top Workplace for the second year in a row.

Yahoo | November 14, 2022

Increasing losses over year doesn't faze Castle Biosciences (NASDAQ:CSTL) investors as stock jumps 11% this past week

Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders should be happy to see the share price up 11% in the last week...

Yahoo | November 3, 2022

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -10% and 7.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 2, 2022

Castle Biosciences Announces Third Quarter 2022 Results

FRIENDSWOOD, Texas, November 02, 2022--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2022.

Yahoo | November 2, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 11.3006 seconds.